GGrantIndex
← Leaderboards

Steven C. Zimmerman

University Of Illinois Urbana-Champaign

$7,523,770
Attributed
$8,602,687
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $732.4K · FY200521
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$8,602,687 · 6

By mechanism

R01$8,602,687 · 6

Top collaborators

Most similar at University Of Illinois Urbana-Champaign

Same institution · by research overlap

Others in their field

Top investigators on “Prevent

Research focus

PreventPolymersDesignStructureBaseSmall MoleculeProtein KinasePrototypeDisease ProgressionCataractMyotonic DystrophyProteinsRna SplicingGenesOligonucleotidesMuscle WeaknessMrna PrecursorNeuromuscularCrosslinkAdultComplexGain Of FunctionNeuromuscular DiseasesSymptoms

Grant awards (32)

Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy$378,792
R01 · FY2021 · AR · contact PI
Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy$474,854
R01 · FY2020 · AR · contact PI
Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy$474,854
R01 · FY2019 · AR · contact PI
Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy$422,055
R01 · FY2018 · AR · contact PI
Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy$17,598
R01 · FY2018 · AR · contact PI
Small Molecule Approaches to Targeting the DNA and RNA in Myotonic Dystrophy$475,337
R01 · FY2017 · AR · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$289,790
R01 · FY2013 · AR · contact PI
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa$261,133
R01 · FY2013 · GM · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$305,043
R01 · FY2012 · AR · contact PI
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa$270,604
R01 · FY2012 · GM · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$305,043
R01 · FY2011 · AR · contact PI
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa$270,604
R01 · FY2011 · GM · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$317,753
R01 · FY2010 · AR
Fluorescent Organic Nanoparticles that are Monovalent, Ultra-Stable, and Biocompa$262,414
R01 · FY2010 · GM · contact PI
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$152,231
R01 · FY2010 · AR
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy$320,963
R01 · FY2009 · AR
Synthetic Antibodies by Monomolecular Imprinting$273,589
R01 · FY2007 · GM · contact PI
Synthetic Antibodies by Monomolecular Imprinting$282,039
R01 · FY2006 · GM · contact PI
TETHERED NUCLEOBASES FOR ENHANCED DNA RECOGNITION$297,513
R01 · FY2005 · GM
Synthetic Antibodies by Monomolecular Imprinting$289,104
R01 · FY2005 · GM
Structural Studies of DNA$0
Z01 · FY2005 · DK
Structure And Stabilization Of The Bacterial Nucleoid$0
Z01 · FY2005 · DK
TETHERED NUCLEOBASES FOR ENHANCED DNA RECOGNITION$297,761
R01 · FY2004 · GM
Synthetic Antibodies by Monomolecular Imprinting$289,373
R01 · FY2004 · GM
Structure And Stabilization Of The Bacterial Nucleoid$0
Z01 · FY2004 · DK
TETHERED NUCLEOBASES FOR ENHANCED DNA RECOGNITION$298,001
R01 · FY2003 · GM
SYNTHETIC ANTIBODIES BY MONOMOLECULAR POLYMER IMPRINTING$239,993
R01 · FY2003 · GM
TETHERED NUCLEOBASES FOR ENHANCED DNA RECOGNITION$287,633
R01 · FY2002 · GM
SYNTHETIC ANTIBODIES BY MONOMOLECULAR POLYMER IMPRINTING$240,222
R01 · FY2002 · GM
SYNTHETIC ANTIBODIES BY MONOMOLECULAR POLYMER IMPRINTING$277,940
R01 · FY2001 · GM
DENDRIMERS--POLYMERS FOR SELF ASSEMBLY AND DRUG DELIVERY$269,098
R01 · FY2001 · GM
DENDRIMERS--POLYMERS FOR SELF ASSEMBLY AND DRUG DELIVERY$261,353
R01 · FY2000 · GM